

[Digoxin](#)

Essential medicine status

Section:

[12. Cardiovascular medicines 12.4. Medicines used in heart failure](#)

ATC codes: [C01AA05](#)

EMLc

Indication

Heart failure ICD11 code: [BD0Z](#)

INN

Digoxin

Medicine type

Chemical agent

List type

Core (EML)

Complementary (EMLc)

Formulations

Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule ; 100 µg per mL in 1 mL ampoule (EMLc)

Oral > Liquid: 50 µg per mL

Oral > Solid > tablet: 62.5 µg ; 250 µg ; 125 µg (EMLc)

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 2007 ([TRS 950](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Digoxin](#)

DrugBank

[Digoxin](#)

Summary of evidence and Expert Committee recommendations



Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for digoxin on the EMLc be transferred from the core to the complementary list, and the addition of new strength dosage forms (injection 100 mcg/mL and tablet 125 mcg) to the EMLc.